- Conditions
- Neoplasms
- Interventions
- SU011248
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 38
- States / cities
- Aurora, Colorado • Littleton, Colorado • Orlando, Florida + 29 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2113–2136
of 7,462
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Epilepsies, Partial
- Interventions
- ganaxolone
- Drug
- Lead sponsor
- Marinus Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more
- Conditions
- Enteral Nutrition, Feeding Tube Placement
- Interventions
- Not listed
- Lead sponsor
- Medtronic - MITG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Motexafin Gadolinium, Temozolomide
- Radiation · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 106
- States / cities
- Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 73 more
- Conditions
- Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Recurrent Uterine Corpus Carcinoma
- Interventions
- Diagnostic Laboratory Biomarker Analysis, Selumetinib
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 72
- States / cities
- Los Angeles, California • Aurora, Colorado • Hartford, Connecticut + 44 more
- Conditions
- ALS
- Interventions
- MT-1186, Placebo
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 384 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Rogers, Arkansas + 30 more
- Conditions
- High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma, Secondary Osteosarcoma
- Interventions
- Bone Scan, Cabozantinib S-malate, Cisplatin, Computed Tomography, Doxorubicin Hydrochloride, Magnetic Resonance Imaging, Methotrexate, Surgical Procedure, X-Ray Imaging
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 40 Years
- Enrollment
- 1,122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 181
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 134 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- RSLV-132, Placebo
- Drug
- Lead sponsor
- Resolve Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 16
- States / cities
- El Cajon, California • La Jolla, California • Los Alamitos, California + 13 more
- Conditions
- Down Syndrome
- Interventions
- Sargramostim for Injection, Saline Placebo
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 35 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Rhabdomyosarcoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Rhabdomyosarcoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
- Interventions
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Pharmacological Study
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 30 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 21 more
- Conditions
- Secondary Hyperparathyroidism, Chronic Kidney Disease
- Interventions
- Etelcalcetide, Cinacalcet, Oral Placebo, Intravenous Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 683 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 41
- States / cities
- Azusa, California • Bakersfield, California • Chula Vista, California + 37 more
- Conditions
- Thrombocytopenia, Neonatal Alloimmune
- Interventions
- Nipocalimab, Intravenous immunoglobulins (IVIG), Prednisone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Sacramento, California • Aurora, Colorado + 13 more
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Bicalutamide, Buserelin, Darolutamide, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Radiation Therapy, Relugolix, Triptorelin
- Drug · Radiation
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 2,050 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 567
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 432 more
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma, Stage III Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer
- Interventions
- Filgrastim, Laboratory Biomarker Analysis, Pegfilgrastim, Topotecan Hydrochloride, Veliparib
- Biological · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 78
- States / cities
- Orange, California • Aurora, Colorado • Hartford, Connecticut + 56 more
- Conditions
- Asthma, Cockroach Hypersensitivity
- Interventions
- Glycerinated German Cockroach Allergenic Extract
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 8 Years to 55 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Cincinnati, Ohio + 1 more
- Conditions
- Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Restrictive Cardiomyopathy
- Interventions
- Not listed
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- Not listed
- Enrollment
- 544 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • Miami, Florida • Chicago, Illinois + 8 more
- Conditions
- Polypharmacy, Alzheimer Disease and Related Dementias
- Interventions
- Pharmacist-led deprescribing intervention
- Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Baltimore, Maryland
- Conditions
- Open Angle Glaucoma, Ocular Hypertension
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Overweight, Obesity
- Interventions
- zenagamtide, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 950 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 41
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Montgomery, Alabama + 36 more
- Conditions
- Sleep-disordered Breathing, Myelomeningocele
- Interventions
- neonatal polysomnography, 2-year Bayley Exam, 2-year polysomnography
- Diagnostic Test
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- Up to 2 Years
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Ann Arbor, Michigan + 6 more
- Conditions
- Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer, Colorectal Cancer, Glioblastoma, Biliary Tract Cancers, Pancreatic Cancer
- Interventions
- Pembrolizumab, Lenvatinib
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 611 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 14
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California + 11 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Afrezza, insulin degludec, Rapid-acting Insulin Analog, Basal Insulin
- Biological
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 19
- States / cities
- Loma Linda, California • Santa Barbara, California • Aurora, Colorado + 15 more
- Conditions
- Kidney Transplantation
- Interventions
- ASKP1240, Tacrolimus, Mycophenolate Mofetil (MMF), Basiliximab, Methylprednisone, Prednisone
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more
- Conditions
- Moderate Aortic Valve Stenosis
- Interventions
- Medtronic Evolut PRO+ TAVR System, or Evolut FX TAVR System, and guideline-directed management and therapy (GDMT)
- Device
- Lead sponsor
- Medtronic Cardiovascular
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2034
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 47 more